We are live on ! Find out more
KALV

KalVista Pharmaceuticals
KALV

Delisted

KALV was delisted on the 10th of June, 2026.

Back to rankings

119 hedge funds and large institutions have $568M invested in KalVista Pharmaceuticals in 2024 Q2 according to their latest regulatory filings, with 19 funds opening new positions, 45 increasing their positions, 33 reducing their positions, and 28 closing their positions.

New
Increased
Maintained
Reduced
Closed

36% more repeat investments, than reductions

Existing positions increased: 45 | Existing positions reduced: 33

2.96% more ownership

Funds ownership: 111.37% → 114.33% (+3%)

2% more capital invested

Capital invested by funds: $557M → $568M (+$11M)

7% less funds holding

Funds holding: 128 → 119 (-9)

15% less call options, than puts

Call options by funds: $373K | Put options by funds: $441K

25% less funds holding in top 10

Funds holding in top 10: 4 → 3 (-1)

32% less first-time investments, than exits

New positions opened: 19 | Existing positions closed: 28

Holders
119
Holders Change
-9
Holders Change %
-7.03%
% of All Funds
1.72%
Holding in Top 10
3
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-25%
% of All Funds
0.04%
New
19
Increased
45
Reduced
33
Closed
28
Calls
$373K
Puts
$441K
Net Calls
-$68K
Net Calls Change
+$5.95M

Top Buyers

Rank Fund Capital Flow
1
Capital World Investors
Capital World Investors
California
+$20.6M
2
VPC
Vestal Point Capital
New York
+$19.2M
3
GPP
Great Point Partners
Connecticut
+$15.6M
4
BlackRock
BlackRock
New York
+$5.99M
5
Vanguard Group
Vanguard Group
Pennsylvania
+$3.56M

Top Sellers

Rank Fund Capital Flow
1
TCM
TCG Crossover Management
California
-$13.8M
2
Marshall Wace
Marshall Wace
United Kingdom
-$6.77M
3
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$6.13M
4
SC
Stempoint Capital
New York
-$4.95M
5
SCM
Soleus Capital Management
Connecticut
-$4.58M
Name Holding Trade Value Shares
Change 		Change in
Stake
PP
126
PDT Partners
New York
– -$498K -41,951 Closed
SCM
127
Superstring Capital Management
New York
– -$380K -32,025 Closed
LNC
128
Lincoln National Corp
Pennsylvania
– -$245K -20,660 Closed
OAM
129
Oxford Asset Management
United Kingdom
– -$244K -20,615 Closed
Millennium Management
130
Millennium Management
New York
– -$229K -19,329 Closed
JF
131
Jump Financial
Illinois
– -$184K -15,500 Closed
AIG
132
American International Group
New York
– -$183K -15,431 Closed
ECM
133
ExodusPoint Capital Management
New York
– -$172K -14,467 Closed
SSA
134
Schonfeld Strategic Advisors
New York
– -$152K -12,800 Closed
SG Americas Securities
135
SG Americas Securities
New York
– -$143K -12,082 Closed
AQR Capital Management
136
AQR Capital Management
Connecticut
– -$125K -10,538 Closed
Principal Financial Group
137
Principal Financial Group
Iowa
– -$121K -10,234 Closed
ET
138
Entropy Technologies
New York
– -$121K -10,172 Closed
SO
139
STRS Ohio
Ohio
– -$42K -3,600 Closed
MLICM
140
Metropolitan Life Insurance Company (MetLife)
New York
– -$21.6K -1,820 Closed
A
141
AlphaQuest
New York
– -$21.3K -1,800 Closed
QL
142
Quarry LP
New York
– -$11.9K -1,000 Closed
Group One Trading
143
Group One Trading
Illinois
– -$4.83K -414 Closed
QCG
144
Quadrant Capital Group
Ohio
– -$961 -81 Closed
GI
145
GAMMA Investing
California
– -$190 -16 Closed
AWM
146
Avior Wealth Management
Nebraska
– -$59 -5 Closed
Carson Wealth (CWM LLC)
147
Carson Wealth (CWM LLC)
Nebraska
– +$350 +30 New
2 3 4 5
6

KALV Hedge Fund Activity: Q2 2024 in Review

119 of the 6,925 institutional investors tracked by Wall St. Rank reported a position in KalVista Pharmaceuticals (KALV) for Q2 2024, worth a combined $568M — up 2% from $557M a quarter earlier.

Sellers outnumbered buyers: 28 funds closed out of KALV and 19 opened new positions — a net loss of 9 holders — while 33 trimmed existing stakes and 45 added.

The largest buyer was Capital World Investors, adding an estimated $20.6M. The largest seller was TCG Crossover Management, exiting entirely with an estimated $13.8M sold.

  • 119 institutional investors held KalVista Pharmaceuticals (KALV) as of Q2 2024, down from 128 in Q1 2024.
  • Funds reported $568M of KalVista Pharmaceuticals stock for Q2 2024, up 2% quarter-over-quarter.
  • 19 funds opened new KalVista Pharmaceuticals positions in Q2 2024 and 28 closed out, a net change of -9 holders.
  • The largest KalVista Pharmaceuticals buyer in Q2 2024 was Capital World Investors, an estimated $20.6M added.
  • The largest KalVista Pharmaceuticals seller in Q2 2024 was TCG Crossover Management, an estimated $13.8M sold.

Based on aggregated 13F filings for Q2 2024.